Who
Suzanne Louise Bruhn
Director
Company insider
Files Form 4 as: Director, Definium Therapeutics; Director, Travere Therapeutics; Director, Vigil Neuroscience; Director, Pliant Therapeutics; Director, Avalo Therapeutics; Director, Spyre Therapeutics; Director, Novelion Therapeutics; Director, Raptor Pharmaceutical.
In numbers
- Trades disclosed
- 114
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $905K
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 11 Apr 2011
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,666 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,188 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,188 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,666 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —24,073 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —18,068 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —33,875 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —13,928 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —24,310 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscienceoption or derivative | SEC FORM 4 Code D | —6,235 | filing |
| 5 Aug 2025filed 5 Aug 2025 | Vigil Neuroscience | SEC FORM 4 Code D | —5,000 | filing |
| 12 Jun 2025filed 16 Jun 2025 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,187 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | Vigil Neuroscience | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.